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Purpose: To assess whether loci other than GLC3A, GLC3B, and GLC3C are linked to primary congenital glaucoma
(PCG).
Methods: The gene CYP1B1 at GLC3A was screened in 19 Iranian PCG probands who had been recruited mostly from
among individuals of Turkish ethnicity and individuals from central and eastern Iran. The gene MYOC was screened in
patients from this cohort who lacked CYP1B1 mutations and in ten patients previously shown not to carry CYP1B1
mutations. Family members of 19 probands without mutations in either of these genes were recruited for assessment of
linkage to GLC3B and GLC3C by genotyping microsatellite markers. In total, 127 individuals, including 35 affected with
PCG, were genotyped.
Results: Eleven (57.9%) of the newly recruited PCG patients did not carry disease-associated mutations in CYP1B1.
Disease-associated MYOC mutations were not observed in any of the patients screened. Inheritance of PCG in all the
families was consistent with an autosomal recessive pattern. Linkage to GLC3B and GLC3C was ruled out in nine of the
families on the basis of autozygosity mapping and haplotype analysis.
Conclusions: Observation of the absence of linkage to GLC3B and GLC3C in at least nine families without CYP1B1
mutations suggests that at least one PCG-causing locus other than GLC3A, GLC3B, and GLC3C may exist. The disease-
causing gene or genes in the novel locus or loci may account for PCG in a notable fraction of Iranian patients.
Primary congenital glaucoma (PCG; OMIM 231300) is
a severe form of glaucoma that develops early in life, usually
in the neonatal period or before the age of three years [1]. It
is characterized by an anatomical defect in the trabecular
meshwork  (trabeculodysgenesis),  and  its  clinical  features
include  increased  intraocular  pressure,  globe  enlargement
(buphthalmos), corneal enlargement, Descemet’s membrane
rupture, corneal edema and opacification, and optic nerve
damage. PCG occurs in both familial and sporadic patterns
[1,2].  Inheritance  in  familial  cases  is  usually  autosomal
recessive.  The  incidence  of  PCG  is  geographically  and
ethnically  variable,  estimated  at  1:10,000  in  Western
countries and higher in inbred populations — for example,
1:2,500 in Saudi Arabia [1,2].
Three PCG loci have been identified by linkage analysis
in multiply affected families: GLC3A [3], GLC3B [4], and
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GLC3C [1,5] (GLC is the designation used for glaucoma loci,
and the numeral 3 refers to the congenital form). The gene
associated  with  GLC3A,  cytochrome  P450,  family  1,
subfamily B, polypeptide 1 (CYP1B1; OMIM 601771), was
identified in 1997 [6]. CYP1B1 is a member of the cytochrome
P450 superfamily of genes. Although physiological studies
have confirmed that mutations in CYP1B1 can cause disease,
the pathway by which CYP1B1 affects development of the
anterior  chamber  of  the  eye  is  unknown.  Presumably,
mutations in the gene result in aberrant metabolism of a PCG-
relevant endogenous substrate of the coded cytochrome P450
enzyme. The proportion of PCG patients whose disease is due
to CYP1B1 mutations is generally high, but it varies among
populations, ranging from 100% in Slovakian Roma to ~20%
in Japan [7,8]. It has been observed that nearly 70% of an
Iranian  cohort  of  PCG  patients  carried  disease-associated
mutations in CYP1B1 and that 30% did not [9]. Although more
than ten years have passed since the identification of the
GLC3B locus, the disease-causing gene at this locus has not
yet  been  identified  [4].  GLC3C  was  reported  in  2002.
Recently,  PCG-causing  mutations  in  latent  transforming
growth  factor  beta  binding  protein  2  (LTBP2;  OMIM
602091) were identified in Pakistani, European Gypsy, and
Iranian patients [10,11]. LTBP2 lies very close to GLC3C on
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2155chromosome  14,  but  it  is  not  strictly  within  the  locus  as
originally defined by microsatellite markers [5]. As such, it is
not clear whether LTBP2 is the PCG-associated gene within
GLC3C  or  whether  the  gene  within  this  locus  remains
unknown and LTBP2 defines a fourth locus for PCG. Based
on structural properties, LTBP2 is a member of a superfamily
of proteins composed of fibrillins and latent transforming
growth factor beta binding proteins [12–14]. Although the
precise  function  of  LTBP2  remains  unknown,  there  is
evidence for LTBP2 having roles in tissue repair processes,
cell adhesion, and functions related to those of microfibrils
and elastin fibers [15–17]. In addition to said loci and genes
associated with PCG, mutations in the gene coding myocilin
(MYOC)  —  a  gene  generally  associated  with  early-onset
primary  open  angle  glaucoma  —  occasionally  have  been
reported in PCG patients [18,19].
In this report, we show by means of local autozygosity
mapping and haplotype analysis restricted to chromosomal
regions of known loci in 19 Iranian PCG families without
CYP1B1 and MYOC mutations that at least one novel PCG-
associated locus is likely to exist. The assumption behind
autozygosity mapping is that an affected offspring born to
consanguineous parents has inherited disease-causing alleles
that are identical by descent from both parents. In the case of
families with multiple affected offspring, the assumption is
that the genetic cause of PCG is the same for all affected
siblings within any one family. In such situations, one would
expect all the affected children to have inherited the same
chromosome from their mother and from their father. This
would be reflected by the children harboring the same pair of
haplotypes, which are combinations of alleles for markers on
those chromosomes. Based on these criteria, disease status in
at least 11 of the families did not link to any of the known PCG
loci.
METHODS
This  research  was  performed  in  accordance  with  the
Declaration of Helsinki. All participants or their responsible
guardians consented to participate after being informed of the
nature of the research. Among the 32 PCG patients previously
shown  not  to  harbor  CYP1B1  mutations,  16  cases  were
familial,  and  the  family  members  of  ten  patients  were
available for further study by microsatellite genotype analysis
[9]. Another 19 PCG probands were recruited from Nikoo-
kari  (Tabriz,  Iran),  Farabi  (Esfahan,  Iran),  and  Al-Zahra
(Zahedan, Iran) hospitals and from schools for blind children
located in the same cities as the hospitals. The clinical features
of the newly recruited patients were obtained from hospital
and school records. All patients had been examined at some
point  previous  to  this  study  by  one  or  more  glaucoma
specialists. Four of these patients were blind in one or both
eyes at the time of recruitment. Recorded information on two
patients  was  considered  insufficient,  and  these  were
reexamined by a glaucoma specialist at Al-Zahra hospital in
Zahedan.  Criteria  for  PCG  diagnosis  included  intraocular
pressure  ≥21  mmHg  in  at  least  one  eye;  corneal  edema;
Descemet’s  membrane  rupture;  megalocornea  (corneal
diameter ≥12 mm); and high cup-to-disc ratio, suggesting
glaucomatous optic nerve head damage. Patients with other
ocular  or  systemic  anomalies  were  excluded.  The  newly
recruited patients were screened for mutations in CYP1B1 by
direct sequencing [9]. All patients from the previous and new
cohorts  without  disease-associated  mutations  in  CYP1B1
were screened by direct sequencing for mutations in MYOC
[20]. Sequencing of the CYP1B1and MYOC genes were done
using the ABI BigDye terminator chemistry and an ABI Prism
3700  instrument  (Applied  Biosystems,  Foster  City,  CA).
Family members of patients without  CYP1B1 and MYOC
mutations were then recruited for local autozygosity mapping
and haplotype analysis of loci GLC3B and GLC3C.
RESULTS
The  104  Iranian  PCG-affected  individuals  previously
screened  for  mutations  in  CYP1B1  consisted  mostly  of
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Ultimately, microsatellite genotyping analysis was done
on 19 families. A total of 127 individuals, including 35 PCG-
affected  individuals,  belonging  to  the  19  families  were
genotyped. All individuals designated unaffected were ten
years old or older at time of recruitment. GLC3B spans 1.04
Mb on chromosome 1, and four polymorphic microsatellites
were used to assess absence of linkage to this locus: tel-
D1S228 - D1S402 - D1S407 - D1S507-cen [4]. GLC3C spans
5.77  Mb  on  chromosome  14,  and  five  polymorphic
microsatellites were used to assess absence of linkage to this
locus:  cen-D14S61  -  D14S263  -  D14S1020  -  G10271  -
D14S1000-tel [5]. These markers span close-flanking regions
as well as the loci themselves. The sequences of primers used
for PCR amplification of DNA segments containing these
microsatellites are provided in Table 1. The forward primers
were  fluorescently  labeled  with  6-  carboxyfluorescein  (6-
FAM), 2'-chloro-5'-fluoro-7',8'-fused phenyl-1,4-dichloro-6-
carboxyfluorescein (NED), or hexachloro-fluorescein (HEX)
in combinations that allowed maximal multiplexing. The size
of the amplicons was determined using ABI3730XL (Applied
Biosystems,  Foster  City,  CA).  Assessment  of  absence  of
linkage  was  established  by  visual  inspection.  Absence  of
linkage  to  GLC3B  or  GLC3C  was  surmised  if  affected
children born to consanguineous parents were found not to be
homozygous for the respective markers. In cases of affected
siblings  born  to  non-consanguineous  parents,  absence  of
linkage was surmised if the affected children did not share
common haplotypes for the respective markers, irrespective
of homozygosity. For apparently sporadic cases, linkage was
considered possible if homozygosity was observed, and no
assessment concerning linkage was made if heterozygosity
was observed.patients recruited from hospitals in Tehran that are national
reference centers [9]. The ethnicity of 92 of the 104 patients
was recorded, and most were from western Iran, consistent
with “common knowledge” among glaucoma specialists in
Iran that PCG is most prevalent in that part of the country
(personal  communication,  Shahin  Yazdani  and  Naveed
Nilforushan). Upon screening for mutations in CYP1B1, we
observed  that  14  of  the  26  patients  (53.8%)  of  Turkish
ethnicity,  mostly  from  northwestern  Iran,  did  not  harbor
mutations in CYP1B1, whereas only 16 of the 66 remaining
patients  with  known  ethnicity  (24.2%)  lacked  CYP1B1
mutations (Figure 1) [9]. As one objective of our research on
glaucoma was to identify unknown loci and genes associated
with PCG, our further patient recruitment efforts focused in
part on the northwestern region of Iran and on individuals of
self-reported Turkish ethnicity. Additionally, we emphasized
central and eastern Iran, regions of the country that were
notably underrepresented in the PCG cohort recruited from
the  national  glaucoma  reference  centers  in  Tehran.  This
approach proved to be fruitful, as 11 of the 19 newly recruited
PCG probands (57.9%) were observed not to harbor disease-
associated mutations in CYP1B1, compared with 32 of 104
patients (30.8%) previously recruited at national reference
centers in Tehran (Figure 1). The CYP1B1 mutations present
in eight of the new probands were E37X, G61E (two patients),
E229K, R368H, R390H (two patients), and F445S. All eight
individuals harbored the mutations in the homozygous state.
Mutations in MYOC were not observed in any PCG patients
without CYP1B1 mutations among either the previous or the
new cohort. Two of the 11 new patients at this point chose not
to participate in the microsatellite genotype analysis, leaving
9 newly recruited patients and 10 patients from our previous
recruitment  to  take  part  in  this  portion  of  the  study.  The
clinical features of these 19 probands are presented in Table
2.
Affected individuals in 13 of the 19 families genotyped
with  microsatellite  markers  were  born  to  consanguineous
parents (Table 2). There were multiple affected individuals in
two of the six non-consanguineous families, suggesting that
PCG in these was also familial. The four remaining families
had only one affected child, and the parents reported non-
consanguinity, but they were included in the study because
the parents in all four cases belonged to highly inbred small
villages.  PCG  appeared  in  all  the  families  in  a  manner
consistent  with  autosomal  recessive  inheritance.  Disease
inheritance  was  considered  consistent  with  an  autosomal
recessive  pattern  even  in  the  single  family  (CGL-221)  in
which affected individuals were observed in two consecutive
generations because in this family, the parents themselves had
been born to parents who were first cousins.
Linkage of PCG status to GLC3B could not be rejected
in one consanguineous family with one affected child because
of homozygosity at all markers tested for this locus (Figure
2A).  Furthermore,  linkage  to  this  locus  was  considered
possible in two other families with one affected individual
each, because of homozygosity at one distal marker. Linkage
of PCG to GLC3C also could not be rejected in three multicase
consanguineous families, as the affected individuals in these
families were homozygous for all five markers tested and none
of the unaffected individuals were homozygous for all the
markers (Figure 2B). Linkage of disease to GLC3C in two
additional  families  also  was  considered  possible,  as
homozygosity  at  bordering  markers  was  observed  in  the
affected individuals. PCG appeared sporadic in two of the
remaining 11 cases; as homozygosity was not observed in
these two cases, linkage to the loci could not be assessed.
Linkage to GLC3B and GLC3C was ruled out in nine
families (Table 2). At least one affected child was born to
consanguineous parents (first cousins in all cases) in seven of
these families, yet homozygosity was not observed for the
markers of these loci (Figure 2C). The affected siblings in each
of two non-consanguineous families did not share common
haplotypes as defined by the microsatellite markers.
DISCUSSION
We had shown that 75.8% of patients of non-Turkish ethnicity
in the PCG cohort of our previous study, most of whom were
from western Iran, harbored mutations in CYP1B1 [10]. This
observation  most  likely  reflects  the  expansion  of  founder
CYP1B1  mutations  in  that  region  of  the  country.  This
proposition  is  supported  by  the  observation  that  despite
TABLE 1. SEQUENCES OF PRIMERS USED FOR AMPLIFICATION OF MICROSATELLITE MARKERS.
Marker name Forward primer Reverse primer
GlC3C Markers
D14S61 5'-GTTCCTGCTAAAAGTCAAGTGG-3' 5'- TCAGAGAGGAAGGTTGGACTG -3'
D14S263 5'-TCATCACAGGCCTTCCTATCC-3' 5'-CTAGGACTTGGCGAATGGTTG-3'
D14S1020 5'-GCCTTTACAGAGGGACTCATC-3' 5'-TCTACTGGGAGCTAGGGCAC-3'
G10271 5'-TCTTAGCCAAAAAGTAGACAGTG-3' 5'-AGGACAGGCTACACCCACAG-3'
D14S1000 5'-TTGTATTGCCAACTGGTTGGTG-3' 5'-CCTACTTATGCTTGGGTACACA-3'
GLC3B Markers
D1S228 5'-AAATAACTGCAACATTGAAATGGC-3' 5'-GGGACCATAGTTCTTGGTGAC-3'
D1S402 5'-TAGACAATAGAGTGAGATTTCAG-3' 5'-TATGGCACTTGGAAATTGACTG-3'
D1S407 5'-CTGTGCTAACCACATGGAGAG-3' 5'-AGCACTTCATTCACTTGTCTGG-3'
D1S507 5'-GAGGGGATCTTGGCACTTGG-3' 5'-CTAGGGTTTCTGGAAAATGCTG-3'
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mutations  among  Iranian  PCG  patients,  four  mutations
(G61E, R368H, R390H, and R469W) constituted 76% of the
mutated  CYP1B1  alleles  identified.  It  was  shown  that
chromosomes  of  different  individuals  harboring  the  same
mutation  all  shared  a  common  haplotype  as  defined  by
intragenic single nucleotide polymorphism (SNP) markers,
suggesting a common origin for these chromosomes [10]. The
expansion  of  these  mutations  appears  to  have  been  more
limited in regions beyond western Iran, as reflected by their
lower representations among study participants from outside
the region. Although PCG prevalence is believed to be highest
in western Iran, looking outside this region proved to be useful
for identifying PCG families whose disease status is not due
to mutations in CYP1B1.
Among the PCG probands in the present study, most
belonged to families that were not sufficiently large to allow
assessment  of  definitive  linkage  to  GLC3B  or  GLC3C.
Among the families in which linkage to GLC3C could not be
rejected, genome-wide autozygosity mapping in two families
subsequently confirmed linkage and led to the identification
of disease-associated mutations in LTBP2, attesting to the
power of this approach [11]. (CGL225 is a branch of pedigree
A  in  reference  [11],  and  CGL202  is  pedigree  B  in  that
reference.) LTBP2 is proximal to but outside of GLC3C as
originally defined [5]. LTBP2 has not yet been screened in the
other families in this study for which linkage to GLC3C was
not ruled out. In the present study, local autozygosity mapping
restricted to chromosomal regions of known loci was used as
a tool to reject linkage to known loci rather than to definitively
identify linkage to known loci or to find novel loci. For this
purpose, even small pedigrees may be informative. Rejection
of linkage to known loci of an autosomal recessive disease is
relatively easy in families in which affected children are born
to  consanguineous  parents;  absence  of  homozygous
genotypes at critical markers suggests absence of linkage. In
non-consanguineous families with multiple affected children,
absence of shared haplotypes suggests absence of linkage.
Here, linkage to GLC3B and GLC3C was shown to be
unlikely  in  nine  of  the  19  families  genotyped  with
microsatellite  markers.  The  families  previously  had  been
shown not to harbor mutations in CYP1B1 at GLC3A. The
observations suggest that the PCG-causing genes in a notable
fraction of Iranian PCG families likely are not positioned
within the three known loci, GLC3A, GLC3B, and GLC3C,
and that at least one unknown PCG locus is expected to exist.
The same locus or loci may account for disease in a fraction
of PCG patients in populations wherein CYP1B1 is not a
common cause of the disease [7,21-24]. We now seek to
identify  the  position  of  the  novel  PCG  locus  or  loci  by
genome-wide genotyping. Identification of genes therein is
Figure 1. Distribution in Iran of primary
congenital  glaucoma  patients  who  do
not  carry  CYP1B1  mutations.  The
number  of  chromosomes  of  primary
congenital  glaucoma  (PCG)  patients
recruited from a given area of Iran that
were  observed  not  to  carry  CYP1B1
mutations is shown as the numerator of
each fraction, and the total number of
chromosomes screened in the areas is
shown as the denominator. Fractions not
enclosed in boxes relate to an earlier
screening  effort  [9],  and  fractions
enclosed  in  boxes  refer  to  the  more
recent  recruitment,  which  focused  on
northwestern, central, and eastern Iran.
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.expected to shed light on the etiology of PCG and may help
in the development of improved therapeutics.
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